Related Experiment Video
Updated: Apr 28, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Ferroptosis-Based Nanotherapeutic Strategies to Overcome Temozolomide Resistance in Glioblastoma: A Systematic Review
Yashaswi Sharma1, Arpana Parihar1, Neha Arya1
1Department of Translational Medicine, All India Institute of Medical Sciences, Saket Nagar, Bhopal 462020, MP, India.
Abstract:
Glioblastoma multiforme (GBM) is one of the most aggressive and treatment-resistant forms of brain cancer, posing challenges to modern oncology. Current treatments, including surgery, radiation, and chemotherapy (e.g., Temozolomide or TMZ), often fail due to the inevitable development of drug resistance. TMZ resistance remains a major therapeutic challenge for the reasons that it is the first-line treatment. Recent studies indicate a rising GBM tumour burden and a trend towards earlier age of onset. It highlights the urgent need for evidence-based policymaking and intensified research to address this most difficult-to-treat malignancy in clinical settings. Ferroptosis, a newly recognized type of controlled cell death induced by iron-dependent lipid peroxidation, has emerged as a potential approach to overcome apoptosis resistance and restore drug sensitivity in GBM. This mechanism is modulated by key molecules that can be specifically targeted to either enhance oxidative stress or inhibit antioxidant defences, ultimately leading to tumour cell death. This review conducts a meta-analysis of preclinical evidence to better understand the potential of activating ferroptosis as a key target for developing nanoparticles to resensitize TMZ-resistant GBM cells. Current evidence indicates that combining ferroptosis induction with strategically engineered nanocarrier systems can serve as a novel and effective therapeutic approach to overcome TMZ resistance and advance precision-based GBM treatment.
Insights
Glioblastoma multiforme (GBM) is a challenging brain cancer. Activating ferroptosis using nanoparticles offers a new way to overcome resistance to Temozolomide (TMZ) treatment in GBM.
Area of Science:
- Oncology
- Nanomedicine
- Cell Death Mechanisms
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain cancer with poor treatment outcomes.
- Temozolomide (TMZ) resistance is a significant challenge in GBM therapy, necessitating novel therapeutic strategies.
- Emerging evidence highlights ferroptosis, an iron-dependent cell death pathway, as a promising avenue for cancer treatment.
Purpose of the Study:
- To review preclinical evidence on ferroptosis induction for overcoming Temozolomide (TMZ)-resistant Glioblastoma multiforme (GBM).
- To explore the potential of nanoparticles in sensitizing GBM cells to TMZ through ferroptosis.
- To assess ferroptosis as a therapeutic target for advancing precision-based GBM treatment.
Main Methods:
- A meta-analysis of preclinical studies investigating ferroptosis in GBM.
- Evaluation of nanoparticle-based strategies for ferroptosis induction.
- Analysis of molecular modulators of ferroptosis (oxidative stress and antioxidant defenses).
Main Results:
- Ferroptosis induction shows potential in overcoming apoptosis resistance in GBM.
- Nanoparticle delivery systems can be engineered to enhance ferroptosis.
- Targeting ferroptosis can resensitize Temozolomide (TMZ)-resistant GBM cells.
Conclusions:
- Combining ferroptosis induction with nanocarrier systems presents a novel therapeutic approach for GBM.
- This strategy holds promise for overcoming Temozolomide (TMZ) resistance and improving GBM treatment outcomes.
- Further research into ferroptosis-targeted nanoparticles could advance precision medicine for Glioblastoma multiforme (GBM).
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers